Mastering HER2 in GI Malignancies: Incorporating a Multidisciplinary Approach Into Current and Emerging Management
Kristen Ciombor, MD
James J. Harding, MD
Filippo Pietrantonio, MD
Kanwal Raghav, MD
Management Strategies for Treatment-Emergent Adverse Events (TEAEs) in HER2-Altered Advanced Solid Tumors
Kathleen Moore, MD, MS
Brad McGregor, MD
Targeting HER2 Across Advanced Solid Tumors
Susana Banerjee, MBBS, MA, FRCP, PhD
Shubham Pant, MD, MBBS
Biliary Tract and Pancreatic Cancer: HER2-Targeted ADCs for Gastrointestinal Cancers
Addressing the Unmet Need in HER2-Positive Advanced Solid Tumors: Exploring Response Rates and Duration of Response
Testing for Solid Tumors: Tissue and Liquid Biopsy Approaches Using NGS Technologies for cfDNA and ctDNA Analysis
Endometrial Cancer: HER2-Targeted ADCs: A Promising Approach to Address Unmet Needs
Bladder Cancer: HER2-Targeted ADCs for Genitourinary Cancers
Targeting HER2 in Advanced Solid Tumors: A Comprehensive Understanding of the Rationale and Potential Benefits
ASCO/ESMO 2023 Roundtable: Contextualizing the Latest Advances in HER2-Targeted Therapy for Solid Tumors
Cervical Cancer: HER2-Targeted ADCs – Current Status and Future Directions
Ovarian Cancer: Advances in HER2-Targeted ADCs
Keeping Pace in Lung Cancer - Breaking Barriers: Advances in Treating EGFR Exon 20 Insertions in NSCLC
Heather Wakelee, MD, FASCO
Lyudmila Bazhenova, MD
Keeping Pace in Lung Cancer - HER2: Unveiling New Horizons in NSCLC Treatment
Jacob Sands, MD
Charu Aggarwal, MD, MPH
Advances in Minimally Invasive Screening for Lung Cancer: Breaking Data from Honolulu
Julie A. Barta, MD, ATSF
Peter J. Mazzone, MD, MPH, FCCP
MET Inhibition in Metastatic NSCLC “In the Spotlight”
Paul Paik, MD
D. Ross Camidge, MD, PhD
Keith Kerr, BSc, MB ChB
Loading...
We’re glad to see you’re enjoying Prova Education… but how about a more personalized experience?
Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.